India has given a go-ahead for clinical trials of Russia’s Sputnik V coronavirus vaccine in the country.
Dr. Reddy’s Laboratories, a pharmaceutical firm based in the southern Hyderabad city, and the Russian Direct Investment Fund (RDIF) have been allowed by the Drug Controller General of India (DCGI) to begin phase 2 and phase 3 clinical trials in the South Asian country.
The Indian firm and Russian body reached an agreement for clinical trials in September, but the country’s drug regulator had earlier denied permission.
“As part of the partnership, the RDIF shall supply 100 million doses of the vaccine to Dr. Reddy’s upon regulatory approval in India,” the RDIF tweeted on Saturday.